ReviewVaccines2020
Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy.Immunology · 2022Trial
- Pathology of Red Blood Cells in Patients with SARS-CoV-2.Biomedicines · 2025Article
- A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Efficacy of Kan JangPharmaceuticals (Basel, Switzerland) · 2023Article
- Generation and Functional Analysis of Defective Viral Genomes during SARS-CoV-2 Infection.mBio · 2023Article
- The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.Immunology · 2023Review
- Review
- Generation and functional analysis of defective viral genomes during SARS-CoV-2 infection.bioRxiv : the preprint server for biology · 2022Article
- The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.Archives of toxicology · 2022Article
- Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection.Diagnostics (Basel, Switzerland) · 2021Article
- Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study.Infectious diseases in clinical practice (Baltimore, Md.) · 2021Article
- Safe Return to Exercise after COVID-19 Infection.Sultan Qaboos University medical journal · 2021Article
- Article
- Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients.iScience · 2021Article
- Coronavirus infection: An immunologists' perspective.Scandinavian journal of immunology · 2021Review
- Immunobiology and immunotherapy of COVID-19: A clinically updated overview.Journal of cellular physiology · 2021Review
- Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.Vaccines · 2021Review
- Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19.BMC medicine · 2021Article
- Article
- The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).BioMed research international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the outbreak of the new coronavirus (SARS-CoV-2) infection is spreading globally, great effort is being made to understand the disease pathogenesis and host factors that predispose to disease progression in an attempt to find a window of opportunity for intervention. In addition to the direct cytopathic effect of the virus, the host hyper-inflammatory response has emerged as a key factor in determining disease severity and mortality. Accumulating clinical observations raised hypotheses to explain why some patients develop more severe disease while others only manifest mild or no symptoms. So far, Covid-19 management remains mainly supportive. However, many researches are underway to clarify the role of antiviral and immunomodulating drugs in changing morbidity and mortality in patients who become severely ill. This review summarizes the current state of knowledge on the interaction between SARS-CoV-2 and the host immune system and discusses recent findings on proposed pharmacologic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.